


## HDAC8-IN-1

Cat. No.:	HY-111342		
CAS No.:	1417997-93-3		
Molecular Formula:	C <sub>22</sub> H <sub>19</sub> NO <sub>3</sub>		
Molecular Weight:	345.39		
Target:	HDAC		
Pathway:	Cell Cycle/DNA Damage; Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (144.76 mM; ultrasonic and warming and heat to 60°C)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.8953 mL	14.4764 mL	28.9528 mL
		5 mM		0.5791 mL	2.8953 mL	5.7906 mL
10 mM			0.2895 mL	1.4476 mL	2.8953 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	HDAC8-IN-1 is a HDAC8 inhibitor with an IC <sub>50</sub> of 27.2 nM.
IC <sub>50</sub> & Target	HDAC8 27.2 nM (IC <sub>50</sub> )
In Vitro	HDAC8-IN-1 is a HDAC8 inhibitor with an IC <sub>50</sub> of 27.2 nM in cancer cell lines. HDAC8-IN-1 (compound 22 d) shows antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); HDAC8-IN-1 exhibits

---

cytotoxicity against human lung CL1-5 cells without significant cytotoxicity for normal IMR-90 cells<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

---

- Cell Death Dis. 2021 May 18;12(6):501.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Huang WJ, et al. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. ChemMedChem. 2012 Oct;7(10):1815-24.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA